CYTOSORBENTS CORPORATION (CTSO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
44/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseCTSO / S&P -33.92% / 15.20% |
LoseCTSO / S&P 3.07% / 15.00% |
WinCTSO / S&P 61.11% / 50.40% |
| 2026-Q10/3 |
LoseCTSO / S&P -11.42% / -4.33% |
LoseCTSO / S&P 5.28% / 11.30% |
LoseCTSO / S&P -34.48% / 27.70% |
| 2025-Q40/3 |
LoseCTSO / S&P -31.58% / 2.65% |
LoseCTSO / S&P 4.12% / 9.00% |
LoseCTSO / S&P -65.79% / 13.40% |
| 2025-Q31/3 |
LoseCTSO / S&P -27.03% / 8.12% |
WinCTSO / S&P 23.89% / 4.61% |
LoseCTSO / S&P -51.35% / 13.45% |
| 2025-Q22/3 |
WinCTSO / S&P 28.00% / 10.94% |
WinCTSO / S&P 20.18% / 4.83% |
LoseCTSO / S&P -66.04% / 10.63% |
| 2025-Q12/3 |
WinCTSO / S&P 9.89% / -4.27% |
WinCTSO / S&P 15.37% / 4.98% |
LoseCTSO / S&P -50.85% / 10.57% |
| 2024-Q41/3 |
LoseCTSO / S&P -39.33% / 2.41% |
WinCTSO / S&P 14.51% / 5.25% |
LoseCTSO / S&P -41.54% / 6.15% |
| 2024-Q31/3 |
WinCTSO / S&P 113.37% / 5.89% |
LoseCTSO / S&P -19.48% / 5.89% |
LoseCTSO / S&P -30.19% / 6.11% |
| 2024-Q20/3 |
LoseCTSO / S&P -26.00% / 4.28% |
LoseCTSO / S&P -17.39% / 5.38% |
LoseCTSO / S&P -11.67% / 5.12% |
| 2024-Q10/3 |
LoseCTSO / S&P -14.41% / 10.56% |
LoseCTSO / S&P -13.60% / 5.71% |
LoseCTSO / S&P -16.90% / 5.59% |
| 2023-Q40/3 |
LoseCTSO / S&P -40.96% / 11.69% |
LoseCTSO / S&P -10.39% / 6.81% |
LoseCTSO / S&P -13.33% / 7.78% |
| 2023-Q30/3 |
LoseCTSO / S&P -47.63% / -3.27% |
LoseCTSO / S&P 2.75% / 7.52% |
LoseCTSO / S&P -44.79% / -5.03% |
| 2023-Q20/3 |
LoseCTSO / S&P 6.53% / 8.74% |
LoseCTSO / S&P -3.60% / 9.50% |
LoseCTSO / S&P -27.71% / -8.57% |
| 2023-Q12/3 |
WinCTSO / S&P 117.42% / 7.50% |
LoseCTSO / S&P -14.09% / 10.77% |
WinCTSO / S&P 2.90% / -15.69% |
| 2022-Q42/3 |
WinCTSO / S&P 13.97% / 7.56% |
LoseCTSO / S&P -19.64% / 11.88% |
WinCTSO / S&P 29.31% / -17.99% |
| 2022-Q31/3 |
LoseCTSO / S&P -37.90% / -4.88% |
LoseCTSO / S&P -18.63% / 13.47% |
WinCTSO / S&P 159.46% / -1.41% |
| 2022-Q21/3 |
LoseCTSO / S&P -31.35% / -16.10% |
LoseCTSO / S&P -16.39% / 13.71% |
WinCTSO / S&P 245.83% / 11.04% |
| 2022-Q10/3 |
LoseCTSO / S&P -23.87% / -4.60% |
LoseCTSO / S&P -3.82% / 15.97% |
LoseCTSO / S&P CTSO unavailable / 42.23% |
| 2021-Q40/3 |
LoseCTSO / S&P -48.40% / 11.03% |
LoseCTSO / S&P 5.27% / 15.00% |
LoseCTSO / S&P CTSO unavailable / 96.40% |
| 2021-Q32/3 |
WinCTSO / S&P 7.55% / 0.58% |
WinCTSO / S&P 21.55% / 10.77% |
LoseCTSO / S&P CTSO unavailable / 69.42% |
| 2021-Q21/3 |
LoseCTSO / S&P -13.02% / 8.55% |
WinCTSO / S&P 40.90% / 6.58% |
LoseCTSO / S&P CTSO unavailable / 51.81% |
| 2021-Q12/3 |
WinCTSO / S&P 8.91% / 6.17% |
WinCTSO / S&P 50.70% / -1.06% |
LoseCTSO / S&P CTSO unavailable / 7.39% |
| 2020-Q41/3 |
LoseCTSO / S&P -0.06% / 12.15% |
WinCTSO / S&P 64.35% / -3.72% |
LoseCTSO / S&P CTSO unavailable / -33.42% |
| 2020-Q31/3 |
LoseCTSO / S&P -19.44% / 8.93% |
WinCTSO / S&P 54.57% / -2.04% |
LoseCTSO / S&P CTSO unavailable / -27.10% |
| 2020-Q22/3 |
WinCTSO / S&P 28.07% / 20.54% |
WinCTSO / S&P 37.76% / -0.46% |
LoseCTSO / S&P CTSO unavailable / -27.11% |
| 2020-Q12/3 |
WinCTSO / S&P 100.78% / -19.60% |
WinCTSO / S&P 27.87% / 3.47% |
LoseCTSO / S&P CTSO unavailable / -14.75% |
| 2019-Q41/3 |
LoseCTSO / S&P -23.46% / 9.07% |
WinCTSO / S&P 16.03% / 5.36% |
LoseCTSO / S&P CTSO unavailable / 2.99% |
| 2019-Q31/3 |
LoseCTSO / S&P -23.90% / 1.70% |
WinCTSO / S&P 9.84% / 5.02% |
LoseCTSO / S&P CTSO unavailable / 0.21% |
| 2019-Q21/3 |
LoseCTSO / S&P -12.68% / 4.30% |
WinCTSO / S&P 21.13% / 6.64% |
LoseCTSO / S&P CTSO unavailable / 8.65% |
| 2019-Q11/3 |
LoseCTSO / S&P -6.31% / 13.65% |
WinCTSO / S&P 31.04% / 8.12% |
LoseCTSO / S&P CTSO unavailable / 14.29% |
| 2018-Q41/3 |
LoseCTSO / S&P -37.36% / -13.52% |
WinCTSO / S&P 37.24% / 9.05% |
LoseCTSO / S&P CTSO unavailable / 18.23% |
| 2018-Q32/3 |
WinCTSO / S&P 13.16% / 7.71% |
WinCTSO / S&P 89.06% / 10.21% |
LoseCTSO / S&P CTSO unavailable / 19.06% |
| 2018-Q22/3 |
WinCTSO / S&P 61.70% / 3.43% |
WinCTSO / S&P 85.83% / 9.03% |
LoseCTSO / S&P CTSO unavailable / 14.46% |
| 2018-Q12/3 |
WinCTSO / S&P 8.46% / -0.76% |
WinCTSO / S&P 78.64% / 7.68% |
LoseCTSO / S&P CTSO unavailable / 12.46% |
| 2017-Q41/3 |
LoseCTSO / S&P 4.84% / 6.64% |
WinCTSO / S&P 90.93% / 7.03% |
LoseCTSO / S&P CTSO unavailable / 13.82% |
| 2017-Q32/3 |
WinCTSO / S&P 44.19% / 4.48% |
WinCTSO / S&P 38.51% / 5.68% |
LoseCTSO / S&P CTSO unavailable / 17.57% |
| 2017-Q21/3 |
LoseCTSO / S&P -4.44% / 3.09% |
WinCTSO / S&P 44.71% / 4.83% |
LoseCTSO / S&P CTSO unavailable / 17.74% |
| 2017-Q11/3 |
LoseCTSO / S&P -17.43% / 6.07% |
WinCTSO / S&P 61.76% / 3.67% |
LoseCTSO / S&P CTSO unavailable / 13.32% |
| 2016-Q41/3 |
LoseCTSO / S&P -14.84% / 3.82% |
WinCTSO / S&P 71.26% / 2.09% |
LoseCTSO / S&P CTSO unavailable / 7.05% |
| 2016-Q32/3 |
WinCTSO / S&P 40.66% / 3.85% |
WinCTSO / S&P 110.16% / 0.20% |
LoseCTSO / S&P CTSO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CTSO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -63.94% | 20.78% |
| Annualized return | -63.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CTSO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.48% | 83.14% |
| Annualized return | -48.80% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CTSO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.27% | 319.30% |
| Annualized return | -23.65% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |